(Reuters) – The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals’ add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
(Reporting by Puyaan Singh and Sriparna Roy in Bengaluru; Editing by Shreya Biswas)
